Lesson plan

1SB-LSD

1SB-LSD, or 1BS-LSD, also known as 1-TMSBz-LSD or as 1-(4-(trimethylsilyl)benzoyl)-LSD, is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD). It is thought to be a prodrug of LSD. The drug was encountered online as a novel designer drug in September 2025. 1SB-LSD has been sold in the form of blotter, for instance containing 165 μg per tab. It is the derivative of 1Bz-LSD (SYN-L-018) in which there is a 4-trimethylsilyl group on the benzyl ring. 1SB-LSD was first described in the scientific literature by 2026. It is not an explicitly controlled substance in the United States or in Canada.

Back to article

Article summary

1SB-LSD, or 1BS-LSD, also known as 1-TMSBz-LSD or as 1-(4-(trimethylsilyl)benzoyl)-LSD, is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD). It is thought to be a prodrug of LSD. The drug was encountered online as a novel designer drug in September 2025. 1SB-LSD has been sold in the form of blotter, for instance containing 165 μg per tab. It is the derivative of 1Bz-LSD (SYN-L-018) in which there is a 4-trimethylsilyl group on the benzyl ring. 1SB-LSD was first described in the scientific literature by 2026. It is not an explicitly controlled substance in the United States or in Canada.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.